About: Critically ill SARS-CoV-2 patients display lupus-like hallmarks of extrafollicular B cell activation

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Critically ill SARS-CoV-2 patients display lupus-like hallmarks of extrafollicular B cell activation Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Critically ill SARS-CoV-2 patients display lupus-like hallmarks of extrafollicular B cell activation
Creator	Affiliations, Woodruff, Matthew Wu, Henry Lee, Eun-Hyung Nguyen, Doan Sanz, Ignacio Cashman, Kevin Howell, J Hu, William Ozturk, Tugba Ramonell, Richard Anam, Fabliha Chen, Weirong Derrico, Andrew Estrada, Jacob Haddad, Natalie Jenks, Scott Kyu, Shuya Le, Sang Lee, Saeyun Ley, Ariel Morrison-Porter, Andrea Saini, Ankur
Source	MedRxiv; Medline
abstract	Wide heterogeneity of disease course ranging from asymptomatic spread to respiratory failure and death has become a hallmark of the SARS-CoV-2 pandemic. While this clinical spectrum is well documented, its immunologic underpinnings are less clear. We have therefore, initiated studies of the B cell responses as they would participate in both early effector responses and in the initiation of memory formation. In terms of effector responses, we were particularly interested in the engagement and clinical correlates of the extra-follicular pathway (EF), we recently described in flaring SLE. In this systemic autoimmune disease, the EF pathway is initiated by newly activated naive B cell (aN) leading to large expansion of autoantibody-producing antibody-secreting cells through the generation of an epigenetically primed B cell precursor which are double negative (DN) for naive (IgD) and memory markers (CD27) and lacking expression of CXCR5 and CD21 (DN2). These highly activated D2 cells are also distinguished by high expression of CD11c and T-bet and are TLR7-driven. Both, TLR7-stimulation which is triggered by ssRNA and the central role played by their murine counterparts (typically characterized as Age-Associated B cells), in viral clearance, strongly supported the hypothesis that DN2 cells and the global EF pathway could be prominently engaged in COVID-19 patients. Also of note, EF B cell activation is particularly prominent in SLE patients of African-American ancestry, a population disproportionately represented in severe COVID-19. In this study we find that critically-ill patients with COVID-19 robustly upregulate constituents of the extrafollicular pathway, produce enormous numbers of antibody secreting cells, and lose unique transitional B cell populations that correlate with positive prognosis. This patient cluster associates tightly with biomarkers of poor outcomes and exhibits high rates of mortality. Thus, this B cell phenotype might serve as an immunological marker of severe COVID infection at early stages and could therefore identify a patient subset likely to benefit from targeted immunomodulatory therapy aimed at alleviating disease burden.
has issue date	2020-05-03(xsd:dateTime)
bibo:doi	10.1101/2020.04.29.20083717
bibo:pmid	32511635
has license	medrxiv
sha1sum (hex)	dd2356de0eb734266de56312eff7524fa3b70868
schema:url	https://doi.org/10.1101/2020.04.29.20083717
resource representing a document's title	Critically ill SARS-CoV-2 patients display lupus-like hallmarks of extrafollicular B cell activation
has PubMed identifier	32511635
schema:publication	medRxiv : the preprint server for health sciences
resource representing a document's body	covid:dd2356de0eb734266de56312eff7524fa3b70868#body_text
is schema:about of	named entity 'B cell' named entity 'leading' named entity 'initiation' named entity 'population' named entity 'B cell' named entity 'Critically' named entity 'SARS-CoV-2' named entity 'DESCRIBED' named entity 'LARGE' named entity 'ASYMPTOMATIC' named entity 'T-BET' named entity 'ANTIBODY' named entity 'TLR7' named entity 'SARS-COV-2' named entity 'HIGHLY' named entity 'CLINICAL' named entity 'RECENTLY' named entity 'represented' named entity 'formation' named entity 'central' named entity 'patients' named entity 'B cell' named entity 'CXCR5' named entity 'terms' named entity 'driven' named entity 'typically' named entity 'responses' named entity 'DN2' named entity 'documented' named entity 'highly' named entity 'studies' named entity 'severe' named entity 'disease' named entity 'memory' named entity 'CXCR5' named entity 'memory formation' named entity 'T-bet' named entity '1, 2' named entity 'TLR7' named entity 'SARS-CoV-2' named entity 'asymptomatic' named entity 'extrafollicular' named entity 'Critically ill' named entity 'SARS-CoV-2' named entity 'critical illness' named entity 'CRP' named entity 'viremia' named entity 'plasma cell' named entity 'COVID-19 infection' named entity 'peer review' named entity 'CD38' named entity 'infection' named entity 'CD19+' named entity 'flow cytometric' named entity 'inflammatory disorders' named entity 'peer review' named entity 'PBMCs' named entity 'critically ill' named entity 'humoral' named entity 'CD21'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software